loading page

Long non-coding RNA GAS5 rs145204276 indel polymorphism and cancer risk: A systemic and meta-analysis review
  • +5
  • Arash Poursheikhani,
  • Vahid Reza Askari,
  • Eskandar Taghizadeh ,
  • Negin Nokhandani,
  • Arash Salmaninejad,
  • Gordon A Ferns,
  • Alireza Pasdar,
  • Majid Ghayour-Mobarhan
Arash Poursheikhani
1- Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Author Profile
Vahid Reza Askari
Mashhad University of Medical Sciences
Author Profile
Eskandar Taghizadeh
4- Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
Author Profile
Negin Nokhandani
5- Department of Medical Immunology, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran
Author Profile
Arash Salmaninejad
1- Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Author Profile
Gordon A Ferns
Brighton and Sussex Medical School
Author Profile
Alireza Pasdar
1- Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Author Profile
Majid Ghayour-Mobarhan
Mashhad University of Medical Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Introduction: Cancer is the second most common cause of death globally. It has been demonstrated that long non-coding RNAs (lncRNAs) may play an essential role in cancer development. The lncRNA growth arrest-special 5 (GAS5) is a critical tumor suppressor in many types of human cancers. We have therefore conducted a meta-analysis to determine the association of lncRNA GAS5 rs145204276 indel polymorphism and cancer risk. Methods: A comprehensive literature search in PubMed, Scopus, and Web of Knowledge were conducted up to July 1, 2019. Eligible studies were included in a meta-analysis. All statistical analyses were conducted using the Metagenyo online tool. Results: Our results showed no significant association between the lncRNA GAS5 rs145204276 and cancer risk using all genetic models. In subgroup analysis, the polymorphism demonstrated a significant association with a lower risk of gastric cancer. Sensitivity analysis confirmed the robustness of our results. No publication bias was also identified. Conclusions: Although the lncRNA GAS5 polymorphism is not associated with increased cancer risk, but its polymorphism was associated with a reduced risk of gastric cancer in subgroup analysis. Further studies with larger sample sizes across different ethnicities need to be performed to explore the association’s strength.